Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841447 · ClinicalTrials.gov registry record
Membrane Target Detection for Leukemia Treatment
A clinical trial of Hematological Malignancy, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04841447 is a study of Hematological Malignancy that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 50 participants, below the 116-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04841447, a study of Hematological Malignancy, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.
Conditions Studied
Interventions
- OTHER Study sample collection
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-03-20 |
| Est. Completion | 2027-03-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04841447
The ClinicalTrials.gov registry entry for NCT04841447 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (57% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Study sample collection is the first listed.
NCT04841447 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04841447 about?
NCT04841447 is a clinical study titled "Membrane Target Detection for Leukemia Treatment". Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been ...
What is the current status of trial NCT04841447?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-03-20. Estimated completion is 2027-03-20.
What conditions does trial NCT04841447 study?
This clinical trial studies the following conditions: Hematological Malignancy.
What interventions are being tested in trial NCT04841447?
The interventions under investigation include: Study sample collection (OTHER).
Who is sponsoring clinical trial NCT04841447?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04841447 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
RECRUITING
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Effect of Body Mass on Filgrastim Pharmacokinetics
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.